Compare
Damora Therapeutics, Inc. vs Annexon, Inc. vs Oramed Pharmaceuticals Inc. vs Pliant Therapeutics, Inc.
| Latest fiscal year | Damora Therapeutics, Inc. DMRA | Annexon, Inc. ANNX | Oramed Pharmaceuticals Inc. ORMPRevenue covers only part of its income (partial revenue) | Pliant Therapeutics, Inc. PLRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $0 |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$209.84M | -$206.69M | $64.05M | -$149.34M |
| EPS (Diluted) | $3.98 | -$1.34 | $1.50 | -$2.43 |
| Operating cash flow | -$6.73M | -$186.36M | -$9.14M | -$128.34M |
| Free cash flow | n/a | -$186.49M | -$9.15M | -$128.71M |
| Cash & equivalents | $257.62M | $162.05M | $45.95M | $45.45M |
| Total assets | $260.53M | $277.57M | $230.86M | $225.23M |
| Total liabilities | $20.15M | $65.92M | n/a | $44.02M |
| Shareholders' equity | $240.38M | $211.65M | $199.74M | $181.21M |
| Return on year-end equity | -87.3% | -97.7% | 32.1% | -82.4% |
| Shares outstanding | 1.60M | 149.36M | 39.28M | 61.45M |
Revenue, most recent five fiscal years
| Fiscal year | Damora Therapeutics, Inc. | Annexon, Inc. | Oramed Pharmaceuticals Inc. | Pliant Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | n/a | $0 Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | n/a | $0 Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | n/a | $1.58M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $9.69M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $7.57M Ended 2021-12-31 |